This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
2016 Jun 23;59(12):5604–21. Autotaxin has lysophospholipase D activity leading to tumor cell growth and motility by lysophosphatidic acid production. The Journal of CellBiology. Structure–Activity Relationships of SmallMolecule Autotaxin Inhibitors with a Discrete Binding Mode. 2016 Sep;7(1):11248.
At Aduro, he was responsible for all manufacturing and supply chain activities for the company’s biologics and smallmolecules and managed a transatlantic team. USA) from the period of 2006 to 2016. in CellBiology from Utrecht University. Kenilworth, N.J., Dr. van de Laar holds a M.Sc. About AM-Pharma.
Fascinated by the potential of AI in medical research, I transitioned to BenevolentAI in early 2023 as a Biology Project Leader. There, I supported AI-enabled DD efforts in their smallmolecule portfolio. Driven by an interest in drug discovery Millie joined AstraZeneca after completion of her PhD at the end of 2020.
Traditionally, drug discovery has focused on small-molecule therapeutics, typically with a molecular weight of less than 500 Daltons. 2 Typically, small-molecule drugs target active sites buried inside proteins. What are macrocycles and why are they interesting for drug discovery?
Likarda initially developed CSS to overcome the lack of effective delivery systems for cell therapies. It subsequently demonstrated promise for the administration of peptides, monoclonal antibodies and smallmolecules. 2016 Dec;5(6):877-884. J Endocr Soc. 2020 Oct 30;5(1):bvaa161. doi: 10.1210/jendso/bvaa161. 7] Unger CA.
We organize all of the trending information in your field so you don't have to. Join 15,000+ users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
Let's personalize your content